Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015. by Chetty, T et al.
RESEARCH ARTICLE
Preterm delivery and small-for-gestation
outcomes in HIV-infected pregnant women on
antiretroviral therapy in rural South Africa:
Results from a cohort study, 2010-2015
Terusha Chetty1,2*, Claire Thorne3, Anna Coutsoudis4
1 Africa Health Research Institute, Mtubatuba, KwaZulu-Natal, South Africa, 2 Department of Public Health
Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South
Africa, 3 UCL Great Ormond Street Institute of Child Health, University College London, London, United
Kingdom, 4 Department of Paediatrics and Child Health, School of Clinical Medicine, University of KwaZulu-
Natal, Durban, KwaZulu-Natal, South Africa
* tchetty@africacentre.ac.za
Abstract
Objectives
Increasingly more women conceive on antiretroviral therapy (ART) with non-nucleoside
reverse transcriptase-based regimens. This study assessed the effect of preconception
tenofovir disoproxil fumarate (TDF)-lamivudine (3TC)/emtricitabine (FTC)-efavirenz (EFV)
and post-conception TDF-(3TC/FTC)-EFV (versus other regimens) on preterm delivery
(PTD) and small-for-gestational age (SGA) births.
Methods
We analysed data of 2549 HIV-infected women attending antenatal clinics in KwaZulu-Natal
from 2010 through 2015 in this retrospective cohort study. Preconception, TDF-(3TC/FTC)-
EFV was compared to nevirapine (NVP)-based regimens and other 3-drug EFV-based
regimens. Post-conception, TDF-(3TC/FTC)-EFV was compared to NVP-based ART and
zidovudine (ZDV) prophylaxis. Outcomes included PTD <37 weeks and SGA births. Gener-
alized linear mixed effects were used to fit logistic regression models to account for repeat
pregnancies.
Results
Among 2549 singleton live births, 10.4% (n = 264) were PTD and 10.4% (n = 265) SGA.
PTD declined from 16.3% in 2010 to 9.3% in 2015 and SGA remained stable from 9.9% in
2010 to 10% in 2015.
Preconception NVP-based regimens [adjusted odds ratio (aOR) 0.66; 95% CI 0.27–1.63]
and other 3-drug EFV-based regimens (aOR 0.72; 95% CI 0.24–2.12) were not associated
with PTD versus TDF-(3TC/FTC)-EFV. NVP-based (aOR 0.75; 95% CI 0.40–1.42) and
other 3-drug EFV-based regimens (aOR 1.55; 95% CI 0.76–3.16) were not associated with
SGA births versus TDF-(3TC/FTC)-EFV.
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Post-conception NVP-based ART (1.77; 95% CI 0.89–3.51) and ZDV (1.03; 95% CI
0.68–1.58) were not associated with PTD versus TDF-(3TC/FTC)-EFV. NVP-based ART
(1.55; 95% CI 0.66–3.61) and ZDV (0.89; 95% CI 0.53–1.47) were not associated with SGA
versus TDF-(3TC/FTC)-EFV.
Conclusions
Preconception TDF-(3TC/FTC)-EFV and post-conception TDF-(3TC/FTC)-EFV were not
associated with PTD or SGA, compared with other regimens. Increasing ART use merits fur-
ther study of the optimum ART regimen for safe birth outcomes.
Introduction
Triple antiretroviral therapy (ART) reduces perinatal HIV transmission [1–3] and improves
maternal and infant survival [4,5]. However, ART may increase adverse birth outcomes,
including preterm delivery (PTD) and small-for-gestational age (SGA) births in developed
[6,7] and developing settings [8–11]. Until recently, birth data for ART-exposed pregnancies
mostly came from cohorts in developed countries [6,12–16], frequently with small sample size
[7,17,18] and with more information on protease inhibitor (PI)-based regimens then non-
nucleoside reverse transcriptase inhibitors (NNRTI) [8,19].
In the Promoting Maternal and Infant Survival Everywhere (PROMISE) trial, zidovudine
(ZDV)-based ART [ZDV, lamivudine (3TC) and lopinavir-ritonavir (LPV/r)] and tenofovir-
based ART [tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) and LPV/r] increased
PTD risk versus ZDV alone; TDF-based ART significantly increased PTD risk before 34 weeks
versus ZDV-based ART [8]. In a large Botswana cohort, TDF-FTC-efavirenz (EFV) regimens
were observed to be at least as safe as other regimens and reduced SGA risk [20]. These
findings were confirmed in a Botswana surveillance study where preconception TDF-FTC-
EFV had lower risk for any adverse birth outcome and protected against severe adverse birth
outcomes versus TDF-FTC-nevirapine (NVP) or ZDV-3TC-NVP [21]. Relative to TDF-FTC-
EFV, all regimens increased SGA risk and ZDV-3TC-NVP increased very PTD delivery risk
[21].
South African guidelines for women initiating post-conception ART evolved from dual
therapy with ZDV and NVP (Option A) in 2010 to interrupted ART with TDF-FTC-EFV
(Option B) in 2013 and lifelong ART with TDF-FTC-EFV (Option B+) in 2015 [22–24]. Glob-
ally, South Africa has the largest absolute number of people on ART (3,929,000), with almost
56% of HIV-infected people on ART in 2016 [25,26]. Over 95% of HIV-infected pregnant
women receive ART for prevention of mother-to-child transmission (PMTCT) [27]. As more
women conceive on ART [27–30], PTD and SGA births may become more evident. Our objec-
tive was to determine the association between preconception TDF-(3TC/FTC)-EFV and post-
conception TDF-(3TC/FTC)-EFV and risk of PTD and SGA births, versus other regimens. A
secondary objective was to present annual trends in PTD and SGA births.
Materials and methods
Between 2010 and 2012, HIV-infected pregnant women attending any one of the 17 antenatal
clinics in the Hlabisa HIV Treatment and Care Programme, northern KwaZulu-Natal, South
Africa were eligible for inclusion [31]. Thereafter enrolment was limited to seven clinics within
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the Africa Centre surveillance area which allowed data linkage (clinics were from the original
cohort with 40% of patients generally representative of Hlabisa) [32]; the additional clinic
(Mtubatuba) was one of the busiest in the sub-district [33].
Clinic staff collected antenatal data [31]. Birth outcomes were abstracted from hospital and
clinic records. Antenatal data were linked with HIV clinical data [CD4+, viral load (VL), ART
regimen, initiation dates, and prior PMTCT] [33].
Singleton live births of at least 24 weeks to HIV-infected women with a recorded delivery
birthweight and gestational age between 1 January 2010 and 31 December 2015 were included.
We excluded multiple births given the increased LBW and PTD risk.
ART groups, regimen and timing
Dates of ART initiation or change were retrieved from the HIV clinical database [33]. We cate-
gorised pregnancies as starting ART before pregnancy (“preconception ART”) or “post-con-
ception ARV” (pregnancy-initiated ART or prophylaxis). Preconception ART were classified
into: TDF-(3TC/FTC)-EFV; NVP-based regimens; and other 3-drug EFV-based regimens.
Post-conception ARV were categorized into: TDF-(3TC/FTC)-EFV, NVP-based ART and
ZDV prophylaxis. Preconception, TDF-(3TC/FTC-EFV), other 3-drug EFV-based regimens
[ABC-3TC-EFV; ZDV-3TC-EFV; stavudine (d4T)-3TC-EFV], and NVP-based regimens
(TDF-3TC-NVP; ZDV-3TC-NVP; d4T-3TC-NVP), and post-conception TDF-(3TC/FTC)-
EFV and NVP-based regimens (ZDV-3TC-NVP, TDF-3TC-NVP, d4T-3TC-NVP) were com-
bined as there were no differences in adverse outcomes between individual regimens in crude
and adjusted analyses.
Preconception ART initiation timing was calculated from initiation date to last menstrual
period (LMP). Post-conception ARV initiation was categorized into first, second, or third
trimester.
Definitions
Nurses determined gestational age at the first antenatal visit, using LMP, symphysis-fundal
height, or ultrasound (for hospital referrals). In women without antenatal care (under 0.5% in
both groups), gestational age was estimated by LMP history and infant birth examination. Sur-
veillance birth data were also used to verify gestational age where available. Gestational age
was recorded on the maternal delivery record.
SGA was defined as birthweight below 10th percentile of expected weight for gestational
age [34,35]. Birthweights at or above 10th percentile were appropriate for gestational age
(AGA). Low birth weight (LBW) was birthweight below 2.5 kg. PTD were births before 37
completed pregnancy weeks.
Antenatal clinic type was classified as rural, peri-urban or other (care outside Hlabisa) [36].
Parity data was not collected. As some women experienced additional pregnancies between
2010 and 2015, pregnancies were classified as index or repeat, then categorized as first, second
or third pregnancy (“pregnancy count”). Delivery mode was classified as caesarean section or
vaginal delivery. The last pregnancy CD4+ was used in analyses; for women without post-con-
ception CD4+ measurement, the measure closest to delivery through six weeks postpartum
was used. As pregnancy VLs was not recommended until 2013, only women on preconception
ART had post-conception VLs.
Statistical analysis
Logistic regression models were used to evaluate PTD and SGA risk factors. We ran separate
models by ART initiation timing (preconception or post-conception). Pregnancies with
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regimen switches or on PI-based ART were excluded. Post-conception, we restricted analyses to
women with at least four weeks of antiretroviral exposure to limit lead time bias. To allow for
repeat pregnancies, generalized linear mixed effects accounted for maternal random effects.
Variables considered a priori to be important, maternal age at first post-conception visit
(15–24 years, 25–34 years;35 years), ART timing, CD4+ (0–100, 101–200, 200–350, >350, or
missing) and calendar birth year, were retained in multivariable models [11]. Other covariates
including antenatal clinic type, delivery place, infant sex, and pregnancy count were included
in univariable analyses as potential confounding factors and included in multivariable models
if P value <0.2. As the cohort was designed to determine PMTCT programme effectiveness,
other confounding factors such as diabetes, hypertension, smoking, drug abuse, prior PTD his-
tory, body mass index, food insecurity and other infections were not collected. Interaction
terms were included to determine if age, calendar birth year, or ART timing modified the regi-
men and birth outcomes association, but was not included in the final models as no association
was found.
We needed 3591 women to show 2% difference in PTD between preconception groups and
1186 women to show 3.5% PTD difference in post-conception groups with 80% power at the
0.05 confidence level. Using the current sample size of 968 in the preconception group and
1581 in the post-conception group, the study was powered at under 20% and 30%, respectively.
Two-sided P values<0.05 were considered statistically significant. Analyses were conducted
using Stata 13.1.
Sensitivity analysis
We performed several sensitivity analyses to address issues in population, exposure and out-
come definitions.
To address historical bias, we restricted the analysis to the seven surveillance clinics from
2010–2015 (analysis 1). In a second sensitivity analysis, we excluded deliveries in 2010 and
2011 when birth outcome rates were higher. In analysis 3, we excluded calendar year as an
explanatory variable as this may have been too closely associated with HIV guideline changes.
We also assessed the seven clinics from 2012–2015 to determine whether changes in risk esti-
mates were related to calendar year. We included LBW as an outcome to address the uncer-
tainty around gestational age dating (analysis 4). To address lead time bias, we restricted the
post-conception analysis to those who started ART under 24 weeks allowing sufficient time for
PTD (analysis 5).
Ethics approval and consent to participate
The University of KwaZulu-Natal Biomedical Research Ethics Committee granted ethics
approval for retrospective analysis of routine data collected in Hlabisa and Mtubatuba local
municipalities health centres (BE066/07) and for this analysis (BE002/16). As patient move-
ment within antenatal clinics was dynamic with different entry times, including delivery, reli-
able written informed consent was challenging. We therefore requested a waiver of written
informed consent for pregnancy data linkage (E134/06). Instead, women gave verbal consent
for data linkage.
Results
Of 4435 pregnancies in 4161 HIV-infected women, 299 (6.7%) were unexposed to ART, 1523
(34.3%) had under one month ARV exposure, and 20 (0.5%) had unknown ART timing (Fig
1). Of 2593 pregnancies remaining, 1002 initiate preconception ART and 1591 started post-
conception ARV. Most of the post-conception group were on ZDV-prophylaxis or NNRTI-
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based regimens; we excluded nine pregnancies on d4T/ZDV-3TC-EFV as there were no
adverse outcomes and one pregnancy with PI-based ART. Ten pregnancies on PI-based ART
and 24 with pregnancy regimen changes were excluded from the preconception group, leaving
2549 pregnancies for this analysis; 968 (38.0%) were on preconception ART and 1581 (62.0%)
on post-conception ARV.
Fig 1. Study inclusions and exclusions.
https://doi.org/10.1371/journal.pone.0192805.g001
Preterm delivery and small-for-gestation outcomes in women on antiretroviral therapy in rural South Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0192805 February 22, 2018 5 / 17
Population characteristics
In the preconception group, TDF-(3TC/FTC)-EFV was the predominant regimen (532,
55.0%), 95 of which were TDF-FTC-EFV (17.9%) (Table 1). In the post-conception group,
TDF-(3TC/FTC)-EFV was the predominant regimen (959, 60.7%), 667 of which were
Table 1. Maternal, pregnancy and delivery characteristics by antiretroviral regimen.
Characteristics Preconception ART group (N = 968) Post-conception ARV group (N = 1581)
TDF-(3TC/
FTC)-EFV a
NVP-based
regimen b
Other 3-drug EFV-
based regimen c
TDF-(3TC/FTC)-EFV
initiated in pregnancy d
NVP-based ART
initiated in pregnancy e
ZDV initiated in
pregnancy
(n = 532) (n = 249) (n = 187) (n = 959) (n = 94) (n = 528)
n (%) n (%) n (%) n (%) n (%) n (%)
Maternal age, years
Median (IQR) 30 (26–34) 30 (26–33) 32 (28–36) 27 (23–31) 29 (23–34) 25 (21–30)
15–24 102 (19.2) 37 (14.9) 18 (9.6) 345 (36.0) 30 (31.9) 263 (49.8)
25–34 323 (60.7) 159 (63.9) 101 (54.0) 492 (51.3) 43 (45.7) 223 (42.2)
35 107 (20.1) 53 (21.3) 68 (36.4) 122 (12.7) 21 (22.3) 42 (8.0)
Gestation at first
antenatal visit, weeks
1–12 57 (10.7) 19 (7.6) 14 (7.5) 125 (13.0) 3 (3.2) 54 (10.2)
13–26 219 (41.2) 79 (31.7) 48 (25.7) 541 (56.4) 31 (33.0) 337 (63.8)
27–44 256 (48.1) 151 (60.6) 125 (66.8) 293 (30.6) 60 (63.8) 137 (26.0)
Enrolment clinic
Rural 301 (56.6) 167 (67.1) 134 (71.7) 434 (45.3) 67 (71.3) 334 (63.3)
Peri-urban 223 (41.9) 74 (29.7) 49 (26.2) 519 (54.1) 26 (27.7) 192 (36.4)
Other 7 (1.3) 6 (2.4) 3 (1.6) 4 (0.4) - -
Missing 1 (0.2) 2 (0.8) 1 (0.5) 2 (0.2) 1 (1.1) 2 (0.4)
CD4+ count, cells/mm3
Median (IQR) 494 (328–685) 426 (299–575) 423 (296–593) 437 (285–639) 302 (221–433) 443 (337–601)
0–100 10 (1.9) 6 (2.4) 3 (1.6) 20 (2.1) 6 (6.4) 11 (2.1)
101–200 29 (5.5) 21 (8.4) 12 (6.4) 74 (7.7) 14 (14.9) 31 (5.9)
201–350 77 (14.5) 42 (16.9) 38 (20.3) 233 (24.3) 39 (41.5) 79 (15.0)
>350 295 (55.5) 139 (55.8) 102 (54.6) 517 (53.9) 33 (35.1) 320 (60.6)
Missing 121 (22.7) 41 (16.5) 32 (17.1) 115 (12.0) 2 (2.1) 87 (16.5)
Viral load, copies/ml
1000 294 (55.3) 144 (57.8) 103 (55.1)
>1000 30 (5.6) 24 (9.6) 21 (11.2)
ART initiation timing
Median (IQR), weeks 74 (41–118) 99 (56–142) 148 (86–239)
1st trimester 114 (11.9) 6 (6.4) 62 (11.7)
2nd trimester 563 (58.7) 45 (47.9) 331 (62.7)
3rd trimester 282 (29.4) 43 (45.7) 135 (25.6)
a TDF-3TC-EFV (82.1%); and TDF-FTC-EFV (17.9%)
b ZDV-3TC-NVP (4.8%); d4T-3TC-NVP (57.8%); TDF-3TC-NVP (37.3%)
c ABC-3TC-EFV (1.1%); ZDV-3TC-EFV (8.0%); d4T-3TC-EFV (90.9%)
d TDF-3TC-EFV (30.5%); TDF-FTC-EFV (69.6%)
e ZDV-3TC-NVP (21.3%); d4T-3TC-NVP (7.5%); TDF-3TC-NVP (71.3%)
Insufficient data was available for the pregnancy ARV group
Preconception ART timing was calculated from the date of initiation to the LMP
https://doi.org/10.1371/journal.pone.0192805.t001
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TDF-FTC-EFV (69.6%), 5.9% on NVP-based regimens and 33.4% on ZDV prophylaxis. The
post-conception group were younger than the preconception group. Late third trimester ante-
natal attendance was common across most groups except post-conception TDF-(3TC/FTC)-
EFV and ZDV. Most women attended rural antenatal clinics and had vaginal deliveries in hos-
pital (Tables 1 and 2). Overall, women were relatively healthy with median CD4+ count above
350 cells/mm3, except women on NVP-based (post-conception), consistent with earlier guide-
lines and CD4+ cutoff (Table 1). Preconception, the median VL was 40 copies/ml (undetect-
able) in all ART groups. However, among 616 women with VLs, 75 (12.2%) had VL above
Table 2. Delivery characteristics by antiretroviral regimen.
Characteristics Preconception ART group (N = 968) Post-conception ARV group (N = 1581)
TDF-(3TC/
FTC)-EFV a
NVP-based
regimen b
Other 3-drug EFV-
based regimen c
TDF-(3TC/FTC)-EFV
initiated in pregnancy d
NVP-based ART initiated
in pregnancy e
ZDV initiated in
pregnancy
(n = 532) (n = 249) (n = 187) (n = 959) (n = 94) (n = 528)
n (%) n (%) n (%) n (%) n (%) n (%)
Type of delivery
Caesarean 58 (10.9) 22 (8.8) 13 (7.0) 95 (9.9) 3 (3.2) 46 (8.7)
Vaginal 439 (82.5) 137 (55.0) 88 (47.1) 689 (71.9) 21 (22.3) 241 (45.6)
Missing 35 (6.6) 90 (36.1) 86 (46.0) 175 (18.3) 70 (74.5) 241 (45.6)
Gestational age at
delivery, weeks
Median (IQR) 39 (38–40) 38 (38–40) 39 (38–40) 39 (38–40) 39 (37–40) 39 (38–40)
<32 3 (0.6) 2 (0.8) 1 (0.5) 10 (1.0) - 3 (0.6)
32–33 5 (0.9) 1 (0.4) 1 (0.5) 14 (1.5) 2 (2.1) 6 (1.1)
34–36 41 (7.7) 21 (8.4) 19 (10.2) 82 (8.5) 12 (12.8) 41 (7.8)
37 483 (90.8) 225 (90.4) 166 (88.8) 853 (89.0) 80 (85.1) 478 (90.5)
Preterm delivery
No 483 (90.8) 225 (90.4) 166 (88.8) 853 (89.0) 80 (85.1) 478 (90.5)
Yes 49 (9.2) 24 (9.6) 21 (11.2) 106 (11.0) 14 (14.9) 50 (9.5)
Birthweight (kg)
Median (IQR) 3.1 (2.8–3.4) 3.1 (2.8–3.4) 3.1 (2.7–3.4) 3.1 (2.8–3.4) 2.9 (2.7–3.2) 3.1 (2.8–3.4)
2.5 480 (90.2) 231 (92.8) 171 (91.4) 856 (89.3) 84 (89.4) 482 (91.3)
<2.5 52 (9.8) 18 (7.2) 16 (8.6) 103 (10.7) 10 (10.6) 46 (8.7)
Size for gestation
AGA 475 (89.3) 230 (92.4) 163 (87.2) 864 (90.1) 80 (85.1) 472 (89.4)
SGA 57 (10.7) 19 (7.6) 24 (12.8) 95 (9.9) 14 (14.9) 56 (10.6)
Calendar year of
delivery
2010 - 27 (10.8) 18 (9.6) 58 (6.1) 20 (21.3) 18 (3.4)
2011 14 (2.6) 52 (20.9) 61 (32.6) 108 (11.3) 38 (40.4) 196 (37.1)
2012 51 (9.6) 39 (15.7) 30 (16.0) 70 (7.3) 34 (36.2) 124 (23.5)
2013 106 (19.9) 46 (18.5) 19 (10.2) 141 (14.7) 2 (2.1) 115 (21.8)
2014 216 (40.6) 54 (21.7) 42 (22.5) 350 (36.5) - 49 (9.3)
2015 145 (27.3) 31 (12.5) 17 (9.1) 232 (24.2) - 26 (4.9)
a TDF-3TC-EFV (82.1%); and TDF-FTC-EFV (17.9%)
b ZDV-3TC-NVP (4.8%); d4T-3TC-NVP (57.8%); TDF-3TC-NVP (37.3%)
c ABC-3TC-EFV (1.1%); ZDV-3TC-EFV (8.0%); d4T-3TC-EFV (90.9%)
d TDF-3TC-EFV (30.5%); TDF-FTC-EFV (69.6%)
e ZDV-3TC-NVP (21.3%); d4T-3TC-NVP (7.5%); TDF-3TC-NVP (71.3%)
https://doi.org/10.1371/journal.pone.0192805.t002
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1000 copies/ml (Table 1); 9.3% of pregnancies had VL above 1000 copies/ml in TDF-(3TC/
FTC)-EFV groups (30/324) and 15.4% (45/292) in other 3-drug EFV and NVP-based groups.
Preconception, median ART duration was 91 weeks (interquartile range (IQR) 51 weeks-147
weeks), with women on TDF-(3TC/FTC)-EFV having the shortest duration. Post-conception
groups usually initiated treatment in the second trimester, but 11.5% (182/1581) overall initi-
ated in the first trimester.
Post-conception, PTD by ART start were: 8.2% (15/182) in the first, 9.8% (92/939) in the
second and 13.7% (63/460) in the third trimester. SGA by ART initiation were: 11.5% (21/182)
in the first, 9.9% (93/939) in the second and 11.1% (51/460) in the third trimester.
Preterm delivery and SGA trends over time
Fig 2 shows evolving ART over time, with increased preconception TDF-(3TC/FTC)-EFV
(2.6% in 2011 to 27.3% in 2015) and post-conception EFV-based ART (12% in 2011 to 25.7%
in 2015). No one received preconception TDF-(3TC/FTC)-EFV or post-conception TDF/
FTC/EFV in 2010. Post-conception TDF-3TC-EFV declined in 2012 stopping after 2014; con-
currently TDF-FTC-EFV increased from 2012 aligned with guidelines [24,37]. NVP-based
ART stopped in 2014.
Overall, there were 245 LBW (9.6%) infants, 264 PTDs (10.4%) and 265 SGA infants
(10.4%). Nineteen PTD infants (7.2%) were also SGA. PTDs fluctuated from 16.3% (23/141) in
2010, 6.6% (23/348) in 2012, to 9.3% in 2015 (42/451). SGA births were approximately 10%
through the years, peaking at 13.8% (48/348) in 2012 (Fig 2).
Preconception, PTD declined from 20.0% in 2010 (9/45) to 7.7% in 2015 (15/193). PTD
was ~7% in TDF-(3TC/FTC)-EFV in 2011 (1/14), 2013 (8/106) and 2015, highest in 2014
Fig 2. PTD and SGA trends by year and PMTCT regimen.
https://doi.org/10.1371/journal.pone.0192805.g002
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(11.1%; 24/216). In 2015, PTDs were highest in NVP-based ART and other 3-drug EFV-based
ART (11.8%; 2/17) and lowest in TDF-(3TC/FTC)-EFV ART (7.6%; 11/145). NVP-based ART
had the highest PTDs in 2010 and 2011 (50%; 1/2 and 7/14 respectively).
Preconception, SGAs increased from 6.7% (3/45) in 2010 to 11.7% (23/196) in 2015. SGA
increased from 7.1% (1/14) in TDF-(3TC/FTC)-EFV in 2011 to 13.1% (19/145) in 2015. The
2012 sharp SGA incline was driven by preconception ART: NVP-based (64.3%; 9/14) and
other 3-drug EFV-based ART (10/30; 33.3%).
Post-conception, PTD declined from 14.6% in 2010 (14/96) to 10.5% in 2015 (27/258) with
nadir of 5.7% in 2012 (13/228). PTD in TDF-(3TC/FTC)-EFV was highest in 2011 (13.0%;
14/108) and declined to 11.2% in 2015 (26/232).
Post-conception, SGAs dropped from 11.5% (11/96) in 2010 to 8.5% in 2015 (22/258).
SGAs declined from 10.3% in 2010 (6/58) to 8.2% in 2015 (19/232) in TDF-(3TC/FTC)-EFV
and from 16.7% (3/18) in 2010 to 11.5% (3/26) in 2015 when on ZDV.
Birth outcomes by preconception ART (N = 968)
Preconception regimens were not associated with PTD and SGA in univariable and multivari-
able analyses (Table 3). In the PTD univariable analysis, the adjusted odds ratio (aOR) for
NVP-based and other 3-drug EFV-based regimens was 1.10 (95% CI 0.52–2.31) and 1.35 (95%
CI 0.60–3.05) respectively, compared with TDF-(3TC/FTC)-EFV (Table 3).
Multivariably, adjusting for ART duration, CD4+ count, age, and calendar delivery year,
NVP-based (aOR 0.66; 95% CI 0.27–1.63) and other 3-drug EFV-based regimens (aOR 0.72;
95% CI 0.24–2.12) non-significantly reduced PTD risk versus TDF-(3TC/FTC)-EFV (Table 3).
In univariable analysis, NVP-based regimens non-significantly lowered SGA risk to 0.69
(95% CI 0.40–1.18); other 3-drug EFV-based regimens increased SGA risk to 1.23 (95% CI
0.74–2.04) versus TDF-(3TC/FTC)-EFV (Table 3). Multivariably, NVP-based regimens (aOR
0.75; 95% CI 0.40–1.42) non-significantly reduced SGA risk; the aOR for other 3-drug EFV-
based regimens was 1.55 (95% CI 0.76–3.16) versus TDF-(3TC/FTC)-EFV (Table 3).
In sensitivity analyses (S1 Table), PTD and SGA risk in other regimens versus TDF-(3TC/
FTC)-EFV were not substantially altered by restricting clinics and calendar year or excluding
calendar year (SGA estimates were more precise). When LBW was an outcome, risk for NVP-
based regimens and other 3-drug EFV-based regimens changed to 0.76 and 1.28 (analysis 4),
respectively, with wider confidence intervals than the main PTD analysis.
Birth outcomes by post-conception ARV (N = 1581)
Post-conception ARV was not associated with PTD and SGA in crude and adjusted models
(Table 4). In the univariable analysis, PTD risk was 1.41 (95% CI 0.77–2.57) for NVP-based
ART and 0.84 (95% CI 0.59–1.20) for ZDV prophylaxis versus TDF-(3TC/FTC)-EFV (Table 4).
Multivariably, adjusting for ART timing, age, CD4+, antenatal clinic and calendar delivery
year, NVP-based ART (aOR 1.77; 95% CI 0.89–3.51) and ZDV prophylaxis (aOR 1.03; 95% CI
0.68–1.58) were not associated with PTD versus TDF-(3TC/FTC)-EFV (Table 4).
In univariable analysis, SGA risk for NVP-based ART was 1.74 (95% CI 0.79–3.86) and 1.09
(95% CI 0.72–1.65) for ZDV versus TDF-(3TC/FTC)-EFV. Multivariably, NVP-based ART
(aOR 1.55; 95% CI 0.66–3.61) and ZDV prophylaxis (aOR 0.89; 95% CI 0.53–1.47) were not
associated with SGA risk versus TDF-(3TC/FTC)-EFV.
In sensitivity analysis (S2 Table), a significantly higher PTD risk for NVP-based ART versus
TDF-(3TC/FTC)-EFV was observed (aOR 3.47, 95% CI 1.17–10.31) in the stricter population
definition but the confidence intervals were imprecise. When we restricted to seven clinics and
calendar year 2012–2015, PTD estimates for NVP-based ART were similar to analysis 1 but
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lost significance (aOR 3.53; 95% CI 0.50–24.84). PTD and SGA risk for ZDV prophylaxis was
not substantially altered when restricting clinics or calendar year. LBW estimates for all regi-
mens were substantially lower than PTD risk in the main analysis with improved precision
(analysis 4). When considering lead time bias (analysis 5), PTD risk for NVP-based ART and
ZDV mimicked the main analysis; ZDV PTD risk increased from 1.03 in the main analysis to
1.60 (95% CI 0.94–2.71) and SGA risk was the slightly lower than the main analysis with
improved precision (aOR 0.76; 95% CI 0.46–1.25).
Table 3. Risk factors for PTD and SGA deliveries between 2010 and 2015 in women on preconception ART (N = 968).
Preterm SGA
Characteristic n (%) Unadjusted OR
(95% CI)
P Adjusted OR (95%
CI)
P Unadjusted OR (95%
CI)
P Adjusted OR (95%
CI)
P
ART regimen 968
TDF-(3TC/FTC)-EFV 532
(54.96)
Ref Ref Ref Ref -
NVP-based regimen 249
(25.72)
1.10 (0.52–
2.31)
0.807 0.66 (0.27–1.63) 0.366 0.69 (0.40–1.18) 0.177 0.75 (0.40–1.42) 0.380
Other 3-drug EFV-based
regimen
187
(19.32)
1.35 (0.60–
3.05)
0.465 0.72 (0.24–2.12) 0.550 1.23 (0.74–2.04) 0.431 1.55 (0.76–3.16) 0.226
Time on ART, weeks 968 (100) 1.00 (0.99–
1.00)
0.823 1.00 (0.99–1.01) 0.290 0.99 (0.99–1.00) 0.687 1.00 (0.99–1.00) 0.689
CD4+ category, cells/mm3 968
0–100 19 (1.96) Ref - Ref - Ref - Ref -
101–200 62 (6.40) 1.11 (0.10–
14.3)
0.931 1.31 (0.13–13.66) 0.820 0.77 (0.18–3.21) 0.332 0.49 (0.11–2.24) 0.356
200–350 157
(16.22)
0.70 (0.10–
7.65)
0.771 0.83 (0.09–7.49) 0.866 0.91 (0.25–3.36) 0.647 0.66 (0.17–2.54) 0.542
>350 536
(55.37)
0.83 (0.10–
8.10)
0.869 0.98 (0.12–7.96) 0.981 0.68 (0.19–2.39) 0.407 0.58 (0.16–2.10) 0.405
Missing 194
(20.04)
0.95 (0.10–
9.84)
0.963 1.19 (0.14–10.37) 0.874 0.43 (0.11–1.64) 0.133 0.35 (0.09–1.39) 0.137
Age, years 968
25–34 583
(60.23)
Ref - Ref - Ref - Ref -
15–24 157
(16.22)
1.73 (0.73–
4.09)
0.210 1.72 (0.73–4.01) 0.213 1.33 (0.78–2.25) 0.296 1.28 (0.73–2.27) 0.389
 35 228
(23.55)
1.07 (0.49–
2.32)
0.874 0.98 (0.46–2.07) 0.945 1.05 (0.64–1.72) 0.832 1.03 (0.61–1.76) 0.905
Calendar year of delivery 968
2010 45 (4.65) Ref - Ref - Ref - Ref -
2011 127
(13.12)
0.40 (0.10–
1.66)
0.208 0.34 (0.08–1.51) 0.156 1.11 (0.29–4.23) 0.877 0.79 (0.19–3.23) 0.740
2012 120
(12.40)
0.25 (0.10–
1.13)
0.072 0.19 (0.04–0.98) 0.047 3.92 (1.13–13.6) 0.031 4.16 (1.14–15.07) 0.030
2013 171
(17.67)
0.33 (0.10–
1.31)
0.116 0.24 (0.05–1.13) 0.072 1.51 (0.42–5.38) 0.528 1.62 (0.42–6.24) 0.483
2014 312
(32.23)
0.28 (0.10–
1.10)
0.066 0.17 (0.03–0.93) 0.041 1.23 (0.36–4.24) 0.743 1.40 (0.36–5.41) 0.629
2015 193
(19.94)
0.23 (0.06–
0.98)
0.047 0.13 (0.02–0.82) 0.030 1.86 (0.53–6.49) 0.330 2.30 (0.56–9.34) 0.245
Timing of ART in the preconception groups is calculated from the date of initiation to the last menstrual period
Antenatal clinic type, VL, pregnancy count, delivery place and infant sex were excluded from the model as P>0.2
https://doi.org/10.1371/journal.pone.0192805.t003
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Table 4. Risk factors for preterm and SGA deliveries between 2010 and 2015 in women initiating post-conception ARV (n = 1581).
Preterm SGA
Characteristic n (%) Unadjusted OR
(95% CI)
P Adjusted OR (95% CI) P Unadjusted OR (95% CI) P Adjusted OR (95% CI) P
ART regimen 1581
TDF-(3TC/FTC)-EFV 959
(42.19)
Ref Ref Ref Ref Ref
NVP-based ART 94 (5.95) 1.41 (0.77–2.57) 0.266 1.77 (0.89–3.51) 0.104 1.74 (0.79–3.86) 0.171 1.55 (0.66–3.61) 0.311
ZDV prophylaxis 528
(33.40)
0.84 (0.59–1.20) 0.341 1.03 (0.68–1.58) 0.878 1.09 (0.72–1.65) 0.675 0.89 (0.53–1.47) 0.639
Timing of ART initiation 1581
Second trimester 939
(59.39)
Ref - Ref - Ref - Ref
First trimester 182
(11.51)
0.83 (0.47–1.46) 0.514 0.77 (0.43–1.38) 0.380 1.24 (0.67–2.31) 0.494 1.27 (0.68–2.36) 0.450
Third trimester 460
(29.10)
1.46 (1.04–2.06) 0.030 1.42 (1.01–2.03) 0.050 1.16 (0.75–1.80) 0.504 1.09 (0.70–1.69) 0.710
CD4+ category, cells/
mm3
1581
0–100 37 (2.34) Ref - Ref - Ref - Ref
101–200 119 (7.53) 0.39 (0.14–1.12) 0.081 0.38 (0.13–1.10) 0.074 2.02 (0.46–8.91) 0.352 2.01 (0.44–9.21) 0.370
200–350 351
(22.20)
0.55 (0.23–1.34) 0.188 0.53 (0.21–1.29) 0.162 1.16 (0.29–4.63) 0.836 1.11 (0.27–4.61) 0.884
>350 870
(55.03)
0.51 (0.22–1.19) 0.117 0.48 (0.20–1.15) 0.099 1.36 (0.35–5.26) 0.658 1.43 (0.35–5.81) 0.621
Missing 204
(12.90)
0.49 (0.19–1.26) 0.138 0.43 (0.16–1.14) 0.090 1.52 (0.36–6.33) 0.568 1.72 (0.38–7.74) 0.481
Age, years 1581
25–34 758
(47.94)
Ref - Ref - Ref - Ref -
15–24 638
(40.35)
1.21 (0.87–1.70) 0.260 1.22 (0.86–1.72) 0.266 1.28 (0.82–2.0) 0.277 1.30 (0.83–2.03) 0.241
35 185
(11.70)
0.97 (0.56–1.66) 0.904 0.92 (0.53–1.60) 0.764 0.93 (0.48–1.81) 0.834 0.90 (0.47–1.72) 0.747
Antenatal clinic type 1576
Rural clinic 835
(52.81)
Ref - Ref - Ref - Ref -
Peri-urban 737
(46.62)
0.80 (0.58–1.11) 0.180 0.77 (0.55–1.08) 0.135 0.57 (0.35–0.93) 0.024 0.59 (0.36–0.97) 0.037
Other 4 (0.25) 2.51 (0.26–
24.34)
0.428 2.68 (0.26–27.39) 0.407 - - - -
Missing 5 (0.32) - - - - - - - -
Calendar year of delivery 1581
2010 96 (6.07) Ref - Ref - Ref - Ref -
2011 342
(21.63)
0.71 (0.37–1.38) 0.311 0.74 (0.37–1.47) 0.388 1.02 (0.44–2.34) 0.970 0.99 (0.42–2.34) 0.975
2012 228
(14.42)
0.35 (0.16–0.79) 0.011 0.38 (0.17–0.87) 0.021 0.80 (0.33–1.98) 0.632 0.79 (0.31–2.01) 0.620
2013 258
(16.32)
0.68 (0.34–1.37) 0.284 0.87 (0.42–1.80) 0.704 0.93 (0.39–2.21) 0.862 1.01 (0.41–2.50) 0.985
2014 399
(25.24)
0.88 (0.46–1.66) 0.688 1.20 (0.60–2.40) 0.616 0.89 (0.39–2.04) 0.783 0.92 (0.37–2.25) 0.850
(Continued)
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Risk factors for PTD and SGA
Preconception ART. In adjusted analysis, only calendar delivery year was significantly
associated with preconception PTD and SGA. PTD risk declined over calendar time (to 0.13 in
2015) versus 2010 with wide confidence intervals (95% CI 0.02–0.82). SGA risk increased to
4.16 in 2012 versus 2010, but the confidence interval was wide (95% CI 1.14–15.07) (Table 3)
Post-conception ARV. Multivariably, third trimester initiations increased PTD risk to
1.42 (95% CI 1.01–2.03) with similar effect size as crude analysis. PTD significantly declined to
0.38 in 2012 versus 2010 (95% CI 0.17–0.87) (Table 4).
Attending peri-urban antenatal clinics versus rural clinics lowered SGA risk to 0.57 (95%
CI 0.35–0.93) in univariable analysis with almost no change in effect size in multivariable anal-
ysis. There were no other PTD and SGA risk factors
Discussion
In this study in a high HIV prevalent setting in rural South Africa, 9% of overall deliveries
were PTD and 10% were SGA, with minimal overlap between outcomes. PTD births declined
over time while SGA births remained relatively stable over six years. There were no significant
differences in PTD or SGA risk among women on either preconception or post-conception
TDF-(3TC/FTC)-EFV versus other regimens.
In the current study, PTD rates were lower in 2015, most likely reflecting ART advantages
for maternal health. In 2010, the national PTD rate was 8.0 per 100 births [38]. We showed a
downward PTD trend through 2015 when ART evolved from NVP-based ART and ZDV pro-
phylaxis to TDF-(3TC/FTC)-EFV regimens [31]. The significant PTD risk reduction may
reflect global and national commitment to improve newborn health [39–42], including
expanded ART access [24]. We also report lower PTD and SGA rates than an earlier Hlabisa
study of ART-naïve HIV-infected and -uninfected mothers delivering through 2004, where
21.4% of live born HIV-exposed infants were PTD and 16.6% were SGA [43]. Maternal HIV
infection was significantly associated with SGA birth, but not with PTD, consistent with strong
evidence linking untreated maternal infection to adverse birth outcomes [44]. The 2010 PTD
birth proportion in our study is slightly higher than the Kesho Bora trial (including Hlabisa
patients) ending in 2008 where women initiated post-conception ART from 28 weeks; PTD
risk was 13% on PI-based ART and 11% in the ZDV prophylaxis group [45].
The reasons behind the sharp variation in 2012 SGA and PTD births are unclear, although
several concomitant changes around this time occurred viz: the Hlabisa HIV Programme
funding ending in 2012; and changes to the 2013 treatment guidelines to start pregnant
women on Option B [24]. Sensitivity analysis reflects these fluctuations as preconception SGA
and post-conception PTD estimates became more precise when restricting to 2012–2015 and
then excluding calendar year from models. PTD and SGA rates reported in this study are
lower than other countries like Botswana; our lower rates may reflect survival bias as we were
Table 4. (Continued)
Preterm SGA
Characteristic n (%) Unadjusted OR
(95% CI)
P Adjusted OR (95% CI) P Unadjusted OR (95% CI) P Adjusted OR (95% CI) P
2015 258
(16.32)
0.68 (0.34–1.37) 0.284 0.95 (0.45–2.01) 0.893 0.68 (0.28–1.70) 0.416 0.71 (0.27–1.89) 0.494
Dropped category as predicts failure perfectly
Antenatal clinic type, VL, pregnancy count, delivery place and infant sex were excluded from the model as P>0.2.
https://doi.org/10.1371/journal.pone.0192805.t004
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unable to ascertain neonatal mortality. Moreover, data were collected by routine health staff;
women with pregnancy complications or sicker infants with adverse outcomes may have been
transferred to referral hospitals with consequent incomplete or missing data on adverse birth
outcomes at primary care level. Neonatal morbidity and mortality related to ART are impor-
tant outcomes for future evaluation.
Preconception, there was no difference in PTD when taking TDF-(3TC/FTC)-EFV versus
other regimens in this study. While the adjusted SGA risk was higher in women on NVP-
based regimens versus TDF-(3TC/FTC)-EFV, the difference was not significant. In the
Botswana surveillance cohort, all preconception regimens (including TDF-FTC-NVP and
ZDV-3TC-NVP) had a significantly higher adjusted PTD and SGA risk versus preconception
TDF-FTC-EFV [21].
Post-conception, there was a higher non-significant PTD and SGA risk in the NVP-based
group versus TDF-(3TC/FTC)-EFV in this study. There was no difference in PTD and non-
significant lower risk of SGA births when exposed to ZDV versus TDF-(3TC/FTC)-EFV in
this study. Our findings are consistent with Botswana where there was no difference in PTD in
women initiating TDF-FTC-EFV versus other 3-drug ART or ZDV; SGA births were less com-
mon in women initiating TDF-FTC-EFV versus any other 3-drug ART (aOR 0.4; 95 CI 0.2–
0.7) [20]. In our sensitivity analysis (post-conception ARV) restricted to seven clinics with
data for 2010 to 2015, NVP-based ART had significantly higher PTD risk versus TDF-(3TC/
FTC)-EFV. Since PTD risk was similar when assessing the seven clinics from 2012–2015 and
decreased when calendar year was excluded, it is plausible that the lower TDF-(3TC/FTC)-
EFV event rate in this study reflects unspecified confounding and information bias with less
preterm data collected in the TDF-(3TC/FTC)-EFV group before TDF-FTC-EFV implementa-
tion in 2013.
In terms of other risk factors, only third trimester initiation increased PTD risk versus sec-
ond trimester in the post-conception ARV group in this study. This contrasts to an earlier
South African cohort where early pregnancy ART with NNRTI-based ART increased PTD
[46]. These dissimilar results in our study are likely related to residual confounding, measure-
ment error or selection bias from late third trimester antenatal attendance care with less time
to prevent pregnancy complications and adverse outcomes.
Published results are difficult to synthesize and interpret due to methodological variation,
including disparate study designs (e.g. clinical trial, prospective cohort, retrospective cohort,
surveillance) and analytic approaches, different populations, settings and obstetric care stan-
dards and differing regimens, reflecting time period as well as place. For instance, the
Botswana surveillance cohort included 45% of the country’s birth data and reported higher
PTD and SGA risk overall. Our cohort includes birth outcomes from a district level hospital
and primary health care facilities and excluded stillborn deliveries. Moreover, as none of the
Botswana participants received TDF-3TC-EFV or non-TDF EFV-based regimens [20,21], pre-
dominant South African first line regimens, applicability to the South African context, espe-
cially the preconception group may be limited.
Study strengths include the large pregnancy cohort on predominantly EFV-based ART in a
developing setting. Women who initiated post-conception ARV may be different from women
on ART for their own health; we thus conducted separate analyses for these groups. This study
is generalizable to other resource-limited settings in South Africa.
The main study limitation was heterogeneity between the compared population in both the
pre- and post-conception models. Consequently, ART groups were small, especially NVP-
based ART and preconception other 3-drug EFV-based regimens, resulting in the study not
being sufficiently powered to detect differences with TDF-(3TC/FTC)-EFV. As there were no
differences in birth outcomes between TDF-FTC-EFV and TDF-3TC-EFV (or NVP-based
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regimens) in crude analyses, it is unlikely that combining groups diluted results. We lacked
data on some specific known risk factors for PTD and SGA such as hypertension and other
comorbidities, maternal weight and nutrition and substance use and cannot rule out residual
confounding. In a prior KwaZulu-Natal study, pregnancy smoking, alcohol and illicit drug use
were under 10% [47]. We were unable to validate delivery gestational age which was based on
LMP and physical examination. In sensitivity analysis, LBW outcomes were slightly different
from the PTD post-conception group and vastly different from the preconception group, sug-
gesting more issues around gestational dating in women starting preconception ART. None-
theless, LMP for gestational age assessment is common in South Africa and may be a reliable
gestational age measurement in resource-limited settings [48,49]. PTD risk did not alter sub-
stantially when ART timing was more strictly defined in the post-conception sensitivity analy-
sis suggesting lead time bias is unlikely. We did not include an HIV-uninfected group which
limits our ability to interpret time-related changes from ART versus health system factors.
Conclusions
Preconception TDF-(3TC/FTC)-EFV and post-conception TDF-(3TC/FTC)-EFV was not
associated with PTD and SGA versus other ART. As there was limited power to detect differ-
ences between ART groups, the results should be interpreted with caution. Larger studies are
required to elucidate ART regimens, timing effect, and specific factors that determine safe
birth outcomes in ART-exposed HIV-infected women in this setting.
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